Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an averag

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Confere

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a

Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medi

MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clini

Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum inve

The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.20) per share which beat the a

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track

Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK

BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whiteha

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinica

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC   SEZ6 expression is posit

22,321,887 Shares of Common Stock This prospectus relates to the offer and resale from time to time

MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying

Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, I

MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinic

Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] afte

Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (NASDAQ:WHWK), a clinica

MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "White

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.32) per share which missed the

Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mi

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by White

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by White

Citizens analyst Reni J. Benjamin initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with

MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other em

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.34) per share which missed the

Jones Trading analyst Soumit Roy initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.26) per share which missed the

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced techn

Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos,

Whitehawk Therapeutics announced a multi-year partnership with Tempus AI, but its stock fell 8.81% i

Whitehawk Therapeutics shares are rising Thursday after the company announced a multi-year collabora

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision m

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.76) per share which missed the

Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly earnings of $1.83 per share which beat the a

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.67) per share which missed the analys